Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib plus best supportive care (BSC) compared with placebo plus BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial

被引：1

作者：

Stintzing, Sebastian

Tabernero, Josep

Satoh, Taroh

Dasari, Arvind

Lonardi, Sara

Eng, Cathy

Garcia-Carbonero, Rocio

Elez, Elena

Yoshino, Takayuki

Sobrero, Alberto F.

Yao, James C.

Kasper, Stefan

Arnold, Dirk

Basic, Edin

Granold, Matthias

Petschulies, Marco

Wu, Liwen

Chen, Lucy

Yang, Zhao

Van Cutsem, Eric

机构：

[1] Charite Univ Med Berlin, Dept Hematol Oncol & Canc Immunol, Berlin, Germany

[2] Vall dHebron Hosp Campus, Vall dHebron Inst Oncol, Barcelona, Spain

[3] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Japan

[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[5] Veneto Inst Oncol IOV IRCCS, Med Oncol Unit 1, Padua, Italy

[6] Vanderbilt Ingram Canc Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA

[7] Hosp Univ 12 Octubre Imas12, UCM, Madrid, Spain

[8] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan

[9] Azienda Osped San Martino, Dept Med Oncol, Genoa, Italy

[10] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany

[11] AK Altona, Dept Oncol & Hematol, Asklepios Tumorzentrum Hamburg, Hamburg, Germany

[12] Takeda Pharm Vertrieb GmbH & Co KG, Berlin, Germany

[13] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA

[14] HUTCHMED Int Inc, Florham Pk, NJ USA

[15] Univ Hosp Gasthuisberg Leuven, Gastroenterol Digest Oncol, Leuven, Belgium

[16] KULeuven, Leuven, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

130-231; 261-492-3532-2370-7650-2700; 283-237-255; 261-492-3532-2370-12160; 281-5277-2560; 9; 3; 2; 2461; 1;

D O I：

10.1200/JCO.2024.42.3_suppl.116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：116 / 116

页数：1